We are live on ! Find out more
NKTR icon

Nektar Therapeutics

239 hedge funds and large institutions have $2.88B invested in Nektar Therapeutics in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 74 increasing their positions, 79 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 21

2% more funds holding

Funds holding: 235239 (+4)

0.07% less ownership

Funds ownership: 6.22%6.15% (-0.07%)

5% less call options, than puts

Call options by funds: $11.1M | Put options by funds: $11.8M

6% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 79

15% less capital invested

Capital invested by funds: $3.39B → $2.88B (-$509M)

Holders
239
Holders Change
+4
Holders Change %
+1.7%
% of All Funds
4.16%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
25
Increased
74
Reduced
79
Closed
21
Calls
$11.1M
Puts
$11.8M
Net Calls
-$642K
Net Calls Change
-$1.34M

NKTR Hedge Fund Activity: Q2 2021 in Review

239 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2021, worth a combined $2.88B — down 15% from $3.39B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new NKTR positions and 21 closed out — a net gain of 4 holders — while 74 added to existing stakes and 79 trimmed.

The largest buyer was Camber Capital Management, adding an estimated $27.7M. The largest seller was Fidelity Investments, cutting an estimated $36.6M.

  • 239 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2021, up from 235 in Q1 2021.
  • Funds reported $2.88B of Nektar Therapeutics stock for Q2 2021, down 15% quarter-over-quarter.
  • 25 funds opened new Nektar Therapeutics positions in Q2 2021 and 21 closed out, a net change of +4 holders.
  • The largest Nektar Therapeutics buyer in Q2 2021 was Camber Capital Management, an estimated $27.7M added.
  • The largest Nektar Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $36.6M sold.

Based on aggregated 13F filings for Q2 2021.